Author

M. J. Sikora

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Approach:experimental assay· 6 Research Focus:cell type annotation· 5 Assay:proteomics· 5 Assay:bulk RNA-seq· 4 Research Focus:differential expression· 4 Approach:statistical model· 4 Research Focus:cell signaling & trafficking· 3

Frequent Co-Authors

B. G. Bitler· 4 shared S. Oesterreich· 4 shared E. K. Bordeaux· 3 shared J. L. Sottnik· 3 shared M. T. Shackleford· 3 shared A. Clauset· 2 shared A. V. LEE· 2 shared D. M. Rao· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

B. G. Bitler

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Estrogen regulation and functional role of FGFR4 in estrogen receptor positive breast cancer

K. Ding, L. Chen, K. M. Levine, M. J. Sikora, N. Tasdemir, D. Dabbs, R. Jankowitz, R. S. Hazan, O. S. Shah, J. M. Xavier, A. V. LEE, S. Oesterreich

This study investigates FGFR4's role in endocrine resistance in ER+ breast cancer and finds it does not generally mediate resistance, though HER2-like subtypes may respond to FGFR4 inhibition.

bioRxiv · Mar 18, 2024 · PreprintCancer Biology

The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinoma

L. B. Van Kleunen, M. Ahmadian, M. D. Post, R. J. Wolsky, C. Rickert, K. Jordan, J. Hu, J. K. Richer, N. A. Marjon, K. Behbakht, M. J. Sikora, B. G. Bitler, A. Clauset

The paper uses spatial data from ovarian cancer tumors to show that spatial organization of the immune microenvironment correlates with patient outcomes and can predict treatment response.

bioRxiv · Jan 26, 2024Cancer Biology

Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast

J. L. Sottnik, M. T. Shackleford, C. S. Nesiba, A. L. Richer, Z. Fleischmann, J. M. Swartz, C. E. Rowland, M. Musick, R. Fu, L. R. Myler, P. L. Opresko, S. Mehrotra, E. S. Sokol, J. R. Hesselberth, J. R. Diamond, M. J. Sikora

This study identifies MDC1's role in ER co-regulation and DNA repair dysfunction in ILC, linking it to PARP inhibitor sensitivity.

bioRxiv · Oct 29, 2023Cancer Biology

EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer

Z. Li, T. Li, M. E. Yates, Y. Wu, A. Ferber, L. Chen, D. D. Brown, J. Carroll, M. J. Sikora, G. Tseng, S. Oesterreich, A. V. LEE

The paper establishes the EstroGene database, which compiles 246 experiments from 136 datasets to analyze estrogen receptor regulomes in breast cancer, revealing diverse temporal, context-dependent, and directional responses.

bioRxiv · Jan 30, 2023 · PreprintCancer Biology

WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers

J. L. Sottnik, M. T. Shackleford, F. R. Villagomez, S. Bahnassy, S. Oesterreich, J. Hu, Z. Madak-Erdogan, R. B. Riggins, B. R. Corr, L. S. Cook, L. S. Trevino, B. G. Bitler, M. J. Sikora

This study identifies WNT4's role in regulating cancer metabolism through mitochondrial intracellular signaling in breast and gynecologic cancers, linking genetic variants to metabolic remodeling.

bioRxiv · Jul 15, 2022Cancer Biology

Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive lobular carcinoma of the breast

E. K. Bordeaux, J. L. Sottnik, S. Mehrotra, S. E. Ferrara, A. E. Goodspeed, J. C. Costello, M. J. Sikora

This study identifies MDC1 as a novel ER co-regulator in ILC that promotes ER-driven proliferation and anti-estrogen resistance.

bioRxiv · Dec 16, 2020Cancer Biology

The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval

K. R. Jordan, M. J. Sikora, J. E. Slansky, A. Minic, J. K. Richer, M. R. Moroney, J. C. Costello, A. Clauset, K. Behbakht, T. R. Kumar, B. G. Bitler

This study identifies an IL-6/IER3 inflammatory signaling axis linked to chemo-resistance in ovarian cancer by analyzing pre- and post-chemotherapy tumor microenvironment changes.

Clinical Cancer Research · Dec 1, 2020Peer-reviewedCancer Biology

Estrogen controls mTOR signaling and mitochondrial function via WNT4 in lobular carcinoma cells

M. T. Shackleford, D. M. Rao, E. K. Bordeaux, H. M. Hicks, S. Oesterreich, M. J. Sikora

This study identifies WNT4 as a mediator of estrogen-driven mTOR signaling and mitochondrial function in lobular carcinoma cells, with implications for anti-estrogen resistance.

bioRxiv · Apr 1, 2020Cancer Biology

WNT4 and WNT3A activate cell autonomous Wnt signaling independent of PORCN or secretion

D. M. Rao, E. K. Bordeaux, T. M. Yamamoto, B. G. Bitler, M. J. Sikora

The paper shows WNT4 and WNT3A can activate cell-autonomous Wnt signaling without requiring PORCN or secretion.

bioRxiv · May 30, 2019Cell Biology